FASN Antibody - #DF6106

>>买2送1 进行中>>
>>送预制胶 进行中>>
(16)   (8)  
产品: FASN 抗体
货号: DF6106
描述: Rabbit polyclonal antibody to FASN
应用: WB IHC
文献验证: WB, IHC
反应: Human, Mouse, Rat
预测: Zebrafish, Bovine, Horse, Dog
分子量: 272kDa; 273kD(Calculated).
蛋白号: P49327
RRID: AB_2811172

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MS Report
HPLC Report
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
预测:
Zebrafish(89%), Bovine(%), Horse(%), Dog(%)
克隆:
Polyclonal
特异性:
FASN Antibody detects endogenous levels of total FASN.
RRID:
AB_2811172
引用格式: Affinity Biosciences Cat# DF6106, RRID:AB_2811172.
偶联:
Unconjugated. 130
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

[Acyl-carrier-protein] S acetyltransferase; [Acyl-carrier-protein] S malonyltransferase; 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase; 3-oxoacyl-[acyl-carrier-protein] reductase; 3-oxoacyl-[acyl-carrier-protein] synthase; Enoyl-[acyl-carrier-protein] reductase; FAS; FAS_HUMAN; FASN; Fatty acid synthase; MGC14367; MGC15706; OA 519; Oleoyl-[acyl-carrier-protein] hydrolase; SDR27X1; Short chain dehydrogenase/reductase family 27X member 1;

抗原和靶标

免疫原:
Uniprot:

P49327(FAS_HUMAN) >>Visit HPA database.

基因/基因ID:
FASN(2194)
表达:
P49327 FAS_HUMAN:

Ubiquitous. Prominent expression in brain, lung, and liver.

描述:
Fatty acid synthase (FASN) catalyzes the synthesis of long-chain fatty acids from acetyl-CoA and malonyl-CoA. FASN is active as a homodimer with seven different catalytic activities and produces lipids in the liver for export to metabolically active tissues or storage in adipose tissue. In most other human tissues, FASN is minimally expressed since they rely on circulating fatty acids for new structural lipid synthesis (1).Recently, increased expression of FASN has emerged as a phenotype common to most human carcinomas. In breast cancer, immunohistochemical staining showed that the levels of FASN are directly related to the size of breast tumors (2). Studies also showed that FASN is highly expressed in lung and prostate cancers and that FASN expression is an indicator of poor prognosis in breast and prostate cancer (3-5). Furthermore, inhibition of FASN is selectively cytotoxic to human cancer cells (5). Thus, increased interest has focused on FASN as a potential target for the diagnosis and treatment of cancer as well as metabolic syndrome (6,7).
序列:
MEEVVIAGMSGKLPESENLQEFWDNLIGGVDMVTDDDRRWKAGLYGLPRRSGKLKDLSRFDASFFGVHPKQAHTMDPQLRLLLEVTYEAIVDGGINPDSLRGTHTGVWVGVSGSETSEALSRDPETLVGYSMVGCQRAMMANRLSFFFDFRGPSIALDTACSSSLMALQNAYQAIHSGQCPAAIVGGINVLLKPNTSVQFLRLGMLSPEGTCKAFDTAGNGYCRSEGVVAVLLTKKSLARRVYATILNAGTNTDGFKEQGVTFPSGDIQEQLIRSLYQSAGVAPESFEYIEAHGTGTKVGDPQELNGITRALCATRQEPLLIGSTKSNMGHPEPASGLAALAKVLLSLEHGLWAPNLHFHSPNPEIPALLDGRLQVVDQPLPVRGGNVGINSFGFGGSNVHIILRPNTQPPPAPAPHATLPRLLRASGRTPEAVQKLLEQGLRHSQDLAFLSMLNDIAAVPATAMPFRGYAVLGGERGGPEVQQVPAGERPLWFICSGMGTQWRGMGLSLMRLDRFRDSILRSDEAVKPFGLKVSQLLLSTDESTFDDIVHSFVSLTAIQIGLIDLLSCMGLRPDGIVGHSLGEVACGYADGCLSQEEAVLAAYWRGQCIKEAHLPPGAMAAVGLSWEECKQRCPPGVVPACHNSKDTVTISGPQAPVFEFVEQLRKEGVFAKEVRTGGMAFHSYFMEAIAPPLLQELKKVIREPKPRSARWLSTSIPEAQWHSSLARTSSAEYNVNNLVSPVLFQEALWHVPEHAVVLEIAPHALLQAVLKRGLKPSCTIIPLMKKDHRDNLEFFLAGIGRLHLSGIDANPNALFPPVEFPAPRGTPLISPLIKWDHSLAWDVPAAEDFPNGSGSPSAAIYNIDTSSESPDHYLVDHTLDGRVLFPATGYLSIVWKTLARALGLGVEQLPVVFEDVVLHQATILPKTGTVSLEVRLLEASRAFEVSENGNLVVSGKVYQWDDPDPRLFDHPESPTPNPTEPLFLAQAEVYKELRLRGYDYGPHFQGILEASLEGDSGRLLWKDNWVSFMDTMLQMSILGSAKHGLYLPTRVTAIHIDPATHRQKLYTLQDKAQVADVVVSRWLRVTVAGGVHISGLHTESAPRRQQEQQVPILEKFCFTPHTEEGCLSERAALQEELQLCKGLVQALQTKVTQQGLKMVVPGLDGAQIPRDPSQQELPRLLSAACRLQLNGNLQLELAQVLAQERPKLPEDPLLSGLLDSPALKACLDTAVENMPSLKMKVVEVLAGHGHLYSRIPGLLSPHPLLQLSYTATDRHPQALEAAQAELQQHDVAQGQWDPADPAPSALGSADLLVCNCAVAALGDPASALSNMVAALREGGFLLLHTLLRGHPLGDIVAFLTSTEPQYGQGILSQDAWESLFSRVSLRLVGLKKSFYGSTLFLCRRPTPQDSPIFLPVDDTSFRWVESLKGILADEDSSRPVWLKAINCATSGVVGLVNCLRREPGGNRLRCVLLSNLSSTSHVPEVDPGSAELQKVLQGDLVMNVYRDGAWGAFRHFLLEEDKPEEPTAHAFVSTLTRGDLSSIRWVCSSLRHAQPTCPGAQLCTVYYASLNFRDIMLATGKLSPDAIPGKWTSQDSLLGMEFSGRDASGKRVMGLVPAKGLATSVLLSPDFLWDVPSNWTLEEAASVPVVYSTAYYALVVRGRVRPGETLLIHSGSGGVGQAAIAIALSLGCRVFTTVGSAEKRAYLQARFPQLDSTSFANSRDTSFEQHVLWHTGGKGVDLVLNSLAEEKLQASVRCLATHGRFLEIGKFDLSQNHPLGMAIFLKNVTFHGVLLDAFFNESSADWREVWALVQAGIRDGVVRPLKCTVFHGAQVEDAFRYMAQGKHIGKVVVQVLAEEPEAVLKGAKPKLMSAISKTFCPAHKSYIIAGGLGGFGLELAQWLIQRGVQKLVLTSRSGIRTGYQAKQVRRWRRQGVQVQVSTSNISSLEGARGLIAEAAQLGPVGGVFNLAVVLRDGLLENQTPEFFQDVCKPKYSGTLNLDRVTREACPELDYFVVFSSVSCGRGNAGQSNYGFANSAMERICEKRRHEGLPGLAVQWGAIGDVGILVETMSTNDTIVSGTLPQRMASCLEVLDLFLNQPHMVLSSFVLAEKAAAYRDRDSQRDLVEAVAHILGIRDLAAVNLDSSLADLGLDSLMSVEVRQTLERELNLVLSVREVRQLTLRKLQELSSKADEASELACPTPKEDGLAQQQTQLNLRSLLVNPEGPTLMRLNSVQSSERPLFLVHPIEGSTTVFHSLASRLSIPTYGLQCTRAAPLDSIHSLAAYYIDCIRQVQPEGPYRVAGYSYGACVAFEMCSQLQAQQSPAPTHNSLFLFDGSPTYVLAYTQSYRAKLTPGCEAEAETEAICFFVQQFTDMEHNRVLEALLPLKGLEERVAAAVDLIIKSHQGLDRQELSFAARSFYYKLRAAEQYTPKAKYHGNVMLLRAKTGGAYGEDLGADYNLSQVCDGKVSVHVIEGDHRTLLEGSGLESIISIIHSSLAEPRVSVREG

种属预测

种属预测:

score>80的预测可信度较高，可尝试用于WB检测。*预测模型主要基于免疫原序列比对，结果仅作参考，不作为质保凭据。

Species
Results
Score
Horse
100
Bovine
100
Dog
100
Zebrafish
89
Chicken
78
Pig
0
Sheep
0
Xenopus
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

研究背景

功能:

Fatty acid synthetase catalyzes the formation of long-chain fatty acids from acetyl-CoA, malonyl-CoA and NADPH. This multifunctional protein has 7 catalytic activities as an acyl carrier protein.

细胞定位:

Cytoplasm. Melanosome.
Note: Identified by mass spectrometry in melanosome fractions from stage I to stage IV.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
组织特异性:

Ubiquitous. Prominent expression in brain, lung, and liver.

亚基结构:

Homodimer which is arranged in a head to tail fashion Ref.28). Interacts with CEACAM1; this interaction is insulin and phosphorylation-dependent; reduces fatty-acid synthase activity (By similarity).

研究领域

· Environmental Information Processing > Signal transduction > AMPK signaling pathway.   (View pathway)

· Metabolism > Lipid metabolism > Fatty acid biosynthesis.

· Metabolism > Global and overview maps > Metabolic pathways.

· Metabolism > Global and overview maps > Fatty acid metabolism.

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

文献引用

1). PLIN1 suppresses glioma progression through regulating lipid metabolism. Cell death & disease, 2025 (PubMed: 39870645) [IF=8.1]
2). MED15 is upregulated by HIF-2α and promotes proliferation and metastasis in clear cell renal cell carcinoma via activation of SREBP-dependent fatty acid synthesis. Cell death discovery, 2024 (PubMed: 38649345) [IF=7.0]
3). β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway. BIOMEDICINE & PHARMACOTHERAPY, 2021 (PubMed: 33341045) [IF=6.9]

Application: WB    Species: Rat    Sample: hepatic tissue

Fig. 4. β-PAE inhibits the expression of hepatic lipid synthesis-related proteins and genes in HFD-fed rats. (A–F) Western blot analysis on the expression of proteins referred to hepatic lipid synthesis including SREBP-1c, ACC1, p-ACC1, FASN, SCD1 and HMG-CR; (G–H) The mRNA expression of SREBP-1c and HMG-CR. Data are presented as the mean ± SD (n = 6~8). ##p < 0.01 vs. NC group; *p < 0.05, **p < 0.01 vs. Model group.
4). Sirtuin 3‐mediated deacetylation of acyl‐CoA synthetase family member 3 by protocatechuic acid attenuates nonalcoholic fatty liver disease. British Journal of Pharmacology, 2020 (PubMed: 32520409) [IF=6.8]

Application: WB    Species: Mouse    Sample: livers

Figure 3. PCA promotes fatty acid metabolism through SIRT3 activation. (A-E) Western blotting and real-time PCR analysis of hepatic FASN, SREBP-1c, CPT1, Acox1 and PPARα protein (n=5) and mRNA (n=6) levels in mouse livers. *P< 0.05 vs. the WT ND group, #P< 0.05 vs. the WT HFD group, &P< 0.05 vs. the SIRT3−/− ND group. (F-I) The protein expression of FASN, SREBP-1c, CPT1, Acox1, PPARα and SIRT3 was measured by Western blotting (n=5). The mRNA levels of (J) FASN, SREBP-1c (K) CPT1, Acox1 and PPARα were measured with real-time PCR (n=6). *P< 0.05 vs. the si-Control group, #P< 0.05 vs. the si-Control+PA group, &P< 0.05 vs. the si-Control+PA+PCA group.
5). Leptin Silencing Attenuates Lipid Accumulation through Sterol Regulatory Element-Binding Protein 1 Inhibition in Nasopharyngeal Carcinoma. International journal of molecular sciences, 2022 (PubMed: 35628510) [IF=5.6]

Application: IHC    Species: Mouse    Sample:

Figure 5. Leptin inhibition attenuates SREBP1 expression in vivo. (A) Mouse body weights were measured in shcontrol and shleptin groups. (B) IHC was performed to investigate the protein expression levels of SREBP1, FASN, and SCD1 in shcontrol and shleptin xenograft tumors. The quantifications of IHC staining are shown. The data are presented as the mean ± SD. ***: p < 0.001; n.s.: not significant.
6). Methyl Brevifolincarboxylate Attenuates Free Fatty Acid-Induced Lipid Metabolism and Inflammation in Hepatocytes through AMPK/NF-κB Signaling Pathway. International Journal of Molecular Sciences, 2021 (PubMed: 34576229) [IF=5.6]

Application: WB    Species: Human    Sample: SK-HEP-1 cells

Figure 3 Effect of methyl brevifolincarboxylate (MBC) on expression of lipogenesis and lipid oxidation mRNA and proteins in OA-treated SK-HEP-1 cells (A), and primary murine hepatocytes (B). Cells were treated with 0.5 mM of OA, and different concentrations of MBC (0, 20, 40, 60, and 80μM) for 48 h. Total RNA was isolated using a GENEzol reagent and mRNA was measured using qRT-PCR. Target gene mRNA levels were normalized to a reference gene β-actin. (C) Protein expression of FASN, ACC1, SREBP-1c, PPAR-α and (D) p-AMPK were detected by Western blot. All results are expressed as mean ± SD of three independent experiments. Data bars with similar letters were not significantly different (p ≤ 0.05).
7). FGF9 Alleviates the Fatty Liver Phenotype by Regulating Hepatic Lipid Metabolism. Frontiers in Pharmacology, 2022 (PubMed: 35517790) [IF=5.6]

Application: WB    Species: mouse    Sample: liver

FIGURE 2 | Knockdown of FGF9 in the liver of DIO mice exacerbated fatty liver phenotype.. (H) Representative Western blotting analysis of genes involved in lipid synthesis in mice as described in (A).
8). Sex hormone-binding globulin improves lipid metabolism and reduces inflammation in subcutaneous adipose tissue of metabolic syndrome-affected horses. Frontiers in molecular biosciences, 2023 (PubMed: 38146533) [IF=5.0]

Application: WB    Species: Human    Sample: adipose tissue

FIGURE 8 Influence of SHBG treatment of lipid metabolism related modulators interplay in SAT (A–N). The relative expression levels of LPL (A), SCD (B), PNPLA2 (C), PLIN1 (D), PPARA (E), FASN (F) in SAT were analyzed by RT-PCR. Protein levels of LPL (G), PLIN1 (H), FASN (I), SCD1 (J), ATGL (K, L) and HSL (M) were analyzed by Western blot ((N), representative membranes). Representative data are shown as mean ± SD.
9). Selegiline ameliorated dyslipidemia and hepatic steatosis in high-fat diet mice. International Immunopharmacology, 2023 (PubMed: 36822098) [IF=4.8]
10). Oxymatrine reduces hepatic lipid synthesis in rat model of nonalcoholic steatohepatitis by regulating Sirt1/AMPK and LXR/Plin2/SREBP-1c pathways. Chemico-biological interactions, 2025 (PubMed: 39746502) [IF=4.7]
加载更多

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.